Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: November 17, 2025
Principal Executive Office: Marseille, France
Context: This filing serves as a cover document to distribute a press release (Exhibit 99.1) dated November 17, 2025. The text provided contains only the cover page and signature block; the actual content of the press release is not included in the source text.
Key Financial Metrics
The provided filing text does not contain any financial data. Consequently, the following metrics are unavailable in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
No material changes can be identified as the source text does not include the press release content or comparative financial data.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These details would be contained within the referenced Exhibit 99.1, which is not present in the input.
Investor Verification Checklist
- Verify the content of the attached Press Release (Exhibit 99.1) to understand the specific event triggering this filing.
- Confirm if the press release contains updated clinical trial data, partnership announcements, or financial results.
- Review the company's most recent Form 20-F for the latest audited financial statements, as this 6-K does not include them.